相关实验视频
Updated: Jul 17, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.5K
在涉及帕金森病患者的交叉试验中的设计问题
David Sparrow1,2, Deborah DeMolles1, Ornella Dubaz1,3
1VA Boston Healthcare System, Boston, MA, United States.
Frontiers in neurology
|September 6, 2023
概括
对于帕金森病的交叉研究,结合转移效应的混合模型提供了不偏见的治疗效应估计. 这种方法优于标准方法,该方法假定洗期消除了转移.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 神经科学研究 神经科学研究
背景情况:
- 交叉设计在帕金森病 (PD) 治疗评估中很常见.
- 标准的PD交叉试验使用洗期,假设消除了转移效应.
- 携带和治疗效应的联合建模在PD交叉研究中很少被应用.
研究的目的:
- 展示一种统一的混合模型,用于评估PD交叉研究中的治疗和转移效应.
- 通过模拟和真实数据分析来评估这种建模方法的性能.
- 将统一模型与PD交叉研究中使用的其他分析方法进行比较.
主要方法:
- 我们比较了三种分析方法:标准交叉t-test,混合模型带带,混合模型没有带带.
- 进行了模拟研究,以评估在转移条件下的方法性能.
- 使用现实世界帕金森病交叉数据示例的插图方法.
主要成果:
- 混合模型,包括转移期和非结构化的相关性矩阵,在模拟中产生了不偏见的治疗效应估计和适当的I型错误率.
- 文献综述表明,大多数PD交叉研究都采用洗期,但没有核实它们是否足以消除转移.
- 提出的混合模型方法成功地用真实PD数据来说明.
结论:
- 建议在PD交叉试验中使用带转期和非结构化的相关性矩阵的混合模型来估计不偏见的治疗效果.
- 强调仅仅依赖于没有明确的转移评估的清洗期的局限性.
- 提倡先进的统计建模以提高PD交叉研究分析的严谨性.
相关概念视频
01:16Crossover Experiments
2.9K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.9K
01:24Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
01:15Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K